Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small… Read more
Market Cap & Net Worth: Summit Therapeutics PLC (SMMT)
Summit Therapeutics PLC (NASDAQ:SMMT) has a market capitalization of $11.61 Billion ($11.61 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5053 globally and #3041 in its home market, demonstrating a -4.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Summit Therapeutics PLC's stock price $15.60 by its total outstanding shares 744442538 (744.44 Million).
Summit Therapeutics PLC Market Cap History: 2015 to 2026
Summit Therapeutics PLC's market capitalization history from 2015 to 2026. Data shows growth from $8.56 Billion to $11.61 Billion (4.23% CAGR).
Index Memberships
Summit Therapeutics PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.09% | #129 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.01% | #597 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.51 Trillion | 0.13% | #80 of 263 |
Weight: Summit Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Summit Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Summit Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4492.27x
Summit Therapeutics PLC's market cap is 4492.27 times its annual revenue
1740.90x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $8.56 Billion | $1.28 Million | -$24.34 Million | 6683.13x | N/A |
| 2016 | $6.37 Billion | $2.88 Million | -$21.37 Million | 2212.65x | N/A |
| 2017 | $8.25 Billion | $17.50 Million | -$28.53 Million | 471.47x | N/A |
| 2018 | $856.11 Million | $56.41 Million | $9.87 Million | 15.18x | 86.72x |
| 2019 | $1.19 Billion | $43.01 Million | $4.99 Million | 27.69x | 238.51x |
| 2020 | $3.50 Billion | $860.00K | -$52.70 Million | 4068.47x | N/A |
| 2021 | $2.00 Billion | $1.81 Million | -$86.15 Million | 1106.99x | N/A |
| 2022 | $3.16 Billion | $704.29K | -$78.78 Million | 4492.27x | N/A |
Competitor Companies of SMMT by Market Capitalization
Companies near Summit Therapeutics PLC in the global market cap rankings as of March 19, 2026.
Key companies related to Summit Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Summit Therapeutics PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Summit Therapeutics PLC's market cap moved from $8.56 Billion to $ 11.61 Billion, with a yearly change of 4.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.61 Billion | -10.81% |
| 2025 | $13.02 Billion | -1.99% |
| 2024 | $13.28 Billion | +583.72% |
| 2023 | $1.94 Billion | -38.59% |
| 2022 | $3.16 Billion | +57.99% |
| 2021 | $2.00 Billion | -42.77% |
| 2020 | $3.50 Billion | +193.75% |
| 2019 | $1.19 Billion | +39.13% |
| 2018 | $856.11 Million | -89.62% |
| 2017 | $8.25 Billion | +29.44% |
| 2016 | $6.37 Billion | -25.57% |
| 2015 | $8.56 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Summit Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.61 Billion USD |
| MoneyControl | $11.61 Billion USD |
| MarketWatch | $11.61 Billion USD |
| marketcap.company | $11.61 Billion USD |
| Reuters | $11.61 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.